theMednetRegister

Medical Oncology

Lymphoma   

Questions discussed in this category

What chemotherapy, if any, would you offer for an elderly patient with congestive heart failure with completely excised Stage I classical Hodgkin lymphoma?
What about if the patient has mediastinal disease and ISRT is not an option?
1 Answer available
When would you use AVD + brentuximab instead of ABVD for newly diagnosed stage 3 or 4 Hodgkin lymphoma?
Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...
2 Answers available
When would you consider treating an asymptomatic patient with follicular lymphoma?
Are there characteristics which could help identify whether a follicular lymphoma might behave more indolently vs aggressively and inform treatment se...
4 Answers available
Can acalabrutinib be used after ibrutinib failure in relapsed/refractory mantle cell lymphoma?
Or would you sequence a different BTKi?
5 Answers available
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...
2 Answers available
How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?
3 Answers available
How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?
DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.
1 Answer available
Is it appropriate to substitute vincristine for vinblastine in ABVD for systemic therapy of Hodgkins lymphoma?
Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...
1 Answer available
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
7 Answers available
What chemotherapy regimen would you offer to a patient with DLBCL who was originally diagnosed and treated (R-CHOP) 15 years ago, now with a 2nd primary/late recurrence of DLBCL?
1 Answer available
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
2 Answers available
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
2 Answers available
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
3 Answers available
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?
4 Answers available
For patients with primary CNS lymphoma and less than a CR to chemotherapy, in what situation would you consider partial or focal radiation?
1 Answer available
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
1 Answer available
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
2 Answers available
Would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes who is otherwise fit for aggressive induction therapy?
TRIANGLE study
2 Answers available
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
1 Answer available
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
Given pelvic RT is likely to induce ovarian dysfunction/menopause, would you consider systemic options?
2 Answers available
What is your preferred salvage therapy for patients with follicular lymphoma who relapsed within 24 months of completing front-line chemoimmunotherapy (POD24) and will proceed to high-dose therapy with Auto-SCT?
Do you have a preference on the regimen or cycle number, and how and when do you assess response prior to transplant?
1 Answer available
What is your preferred induction regimen prior to allo-HCT for mantle cell lymphoma?
1 Answer available
What is the optimal choice of therapy for a patient with Hodgkin variant of Richter's transformation from underlying CLL/SLL?
Does age influence your choice of regimen?
1 Answer available
How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?
Would you continue R-CHOP or would you switch therapy? 
1 Answer available
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
1 Answer available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
How do you approach CNS prophylaxis in patients with DLBCL?
Would you follow an algorithm such as the one proposed by Hall et al., PMID 29940062?How do you decide between intrathecal chemotherapy vs systemic th...
1 Answer available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
2 Answers available
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
1 Answer available
Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?
1 Answer available
How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?
1 Answer available
Is there an optimal salvage radiation dose for relapsed post-CART disease?
1 Answer available
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
2 Answers available
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...
2 Answers available
How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?
Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...
2 Answers available
What salvage chemotherapy, if any, would you recommend for a patient with primary refractory DLBCL who progressed after two cycles of R-CHOP?
5 Answers available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
1 Answer available
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
Is the data sufficient to change your practice?
2 Answers available
Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?
2 Answers available
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?
2 Answers available
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?
2 Answers available
What are the factors that convince you to not immediately treat mantle cell lymphoma and to follow a course of "active surveillance"?
Is there a specific Ki67 percentage? P53-negativity? 
3 Answers available
How do you manage grade 1-3A Follicle Center Lymphoma of the lower female genital tract, presenting with a cervical mass?
How do you pursue fertility preservation in younger females with this presentation?
1 Answer available
How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?
2 Answers available
What treatment considerations do you make for elderly patients with relapsed/refractory follicular lymphoma?
Are you more inclined to use non cytotoxic regimens such as R2 or PI3K inhibitors?
2 Answers available
What therapy do you usually choose in patients with previously treated follicular lymphoma who experience early relapse (< 2 years)?
2 Answers available
What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?
1 Answer available
How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?
1 Answer available
When do you recommend consolidative XRT for patients with advanced stage (III-IV) DLBCL who achieve CR to chemoimmunotherapy?
What XRT dose do you use? Does the location of the disease (e.g., mediastinum) affect your decision when taking toxicity into account? would you offer...
2 Answers available
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
1 Answer available
What is the preferred initial therapy for T-cell lymphoblastic lymphoma in non-AYA, non-elderly adults?
1 Answer available
How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
2 Answers available
How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?
Would your approach differ for a 30 year old and a 70 year old?
3 Answers available
How often should you screen for lymphoma in patients with primary Sjogren's syndrome?
1 Answer available
How would you treat DLBCL of the terminal ileum in an otherwise healthy patient?
1 Answer available
What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?
Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...
1 Answer available
How do you approach a cervical node biopsy-proven follicular lymphoma in situ in a symptomatic patient with night sweats and PET findings of low SUV uptake throughout the body?
Would you biopsy another site or treat the patient? 
1 Answer available
How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?
How do you choose between CAR-T and autoSCT, for example? 
3 Answers available
How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?
1 Answer available
Would it be reasonable to offer a patient with CLL a treatment break from acalabrutinib or any BTK inihibitor after a period of time, assuming good response?
It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about rea...
1 Answer available
How do you manage bruising in patients on ibrutinib?
7 Answers available
How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?
Would you intercalate HD-MTX with her CHOEP?
1 Answer available
How would you treat lymphoplasmacytic lymphoma (LPL) with a non-IgM paraprotein?
Does your treatment approach differ from Waldenstrom's Macroglobulinemia? Does the presence/absence of a MYD88 L265P and/or CXCR4 mutation change you...
1 Answer available
What is your preferred BTK inhibitor for patients with relapsed/refractory mantle cell lymphoma?
How do you generally think about sequencing treatment among available options? Would your choice be affected by a patient's eligibility for transplan...
3 Answers available
How would you approach mantle cell lymphoma in very elderly patients?
2 Answers available
How do you choose bridging therapy prior to CAR-T leukapheresis?
Are there agents (eg. bendamustine) or modalities to avoid? Does washout times prior to collection vary between modalities?
1 Answer available
How would you treat a patient with recurrent DLBCL 15 years after definitive treatment of initial de novo disease with R-CHOP?
1 Answer available
How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?
2 Answers available
Is concurrent intrathecal therapy necessary with HD-MTX for CNS lymphoma?
How do you determine whether to add intrathecal chemotherapy in patients with +CSF? Would your approach change for primary vs secondary CNS lymphoma?
1 Answer available
How would you approach a young patient with stage I follicular lymphoma of the mesenteric lymph nodes?
What treatment margins/set-up/on-board imaging would you use?
1 Answer available
What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?
2 Answers available
How would you approach a patient with high-grade gastric lymphoma who achieved a CR following chemotherapy?
If radiation is indicated, what dose would you use?
1 Answer available
How does your surveillance for DLBCL change given the new role of CAR-T in 2nd line treatment?
How do you assess if a patient may be a candidate for CAR-T cell therapy?
3 Answers available
What is the best approach for patients with DLBCL with early relapse (< 6 months) after initially attaining a CR with 6 cycles RCHOP?
Does this differ for a patient who had a longer remission before relapse?
4 Answers available
How do you prepare patients with DLBCL on the potential need for cellular therapies after progression on first line regimens?
When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...
3 Answers available
How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?
Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...
4 Answers available
How would you treat an elderly patient with CD30 negative PTCL NOS involving base of tongue, vallecula and bilateral cervical lymph nodes?
Would you utilize radiation along with systemic therapy?
1 Answer available
How do you treat a young woman of child bearing age group diagnosed with primary CNS lymphoma?
The CALGB regimen is quite complicated. 
1 Answer available
If a patient had a grade 2 infusion reaction to initial dose of IV Rituximab, can you give subcutaneous Rituximab for cycle 2 or continue with IV Rituximab?
1 Answer available
How do you choose which BTK inhibitor to use in NHL?
Does the safety profile impact your choice significantly? Does your first choice vary by disease histology?
1 Answer available
How do you approach treating a patient with IgM-AL amyloidosis?
Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...
3 Answers available
For primary CNS lymphoma, when do you refer for whole brain radiation therapy (WBRT)?
My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...
1 Answer available
How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?
2 Answers available
How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?
1 Answer available
What treatment would you recommend in an older patient with multiply relapsed double-hit lymphoma with recurrence following ASCT, pola-BR, and CAR-T therapy?
1 Answer available
How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?
1 Answer available
Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?  
2 Answers available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
Are BTK inhibitors safe to use in patients with severe renal failure?
eg. eGFR < 30 ml
1 Answer available
Do you avoid using tafasitamab in germinal center subtype diffuse large B-cell lymphoma?
1 Answer available
Do you routinely offer antiviral prophylaxis for patients receiving chemoimmunotherapy?
If so, what regimen do you utilize?
1 Answer available
In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?
1 Answer available
How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?
1 Answer available
Do you consider EBUS TBNA in the diagnostic evaluation of patients with mediastinal lymphadenopathy with concern for lymphoma?
1 Answer available
How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?
1 Answer available
How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?
Would you give R-CHOP without knowing if there was use of prior anthracycline? 
1 Answer available
How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?
Do you have a preferred sequence of therapies for diffuse skin limited MF?
1 Answer available
What is the role of splenectomy versus systemic therapy in splenic marginal zone lymphoma?
2 Answers available
How do you treat primary refractory diffuse large B cell lymphoma in elderly patients with good performance status?
1 Answer available
Do you give an etoposide-based regimen/more aggressive therapy for lymphoma-associated HLH, such as da-EPOCH-R over R-CHOP?
What about changing standard regimens for TCL with HLH?
1 Answer available
How do you manage severe thrombocytopenia due to splenomegaly and bone marrow involvement in CLL when starting obinituzumab and venetoclax?
1 Answer available
How would you treat a young patient with classical intermediate-risk Hodgkin lymphoma who has an underlying DNA repair-deficiency disorder, such as congenital mismatch repair disorder or ataxia telangiectasia?
How does your treatment approach vary depending on the underlying predisposition?
1 Answer available
How will you use Pola-R-CHP in the frontline treatment of DLBCL?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...
2 Answers available
How would you approach older patients who are not fit or frail with stage 1 favorable classical Hodgkin lymphoma?
Is there any role for radiation therapy alone? 
1 Answer available
What is your approach to a patient with an advanced stage diffuse large B-cell lymphoma treated with chemotherapy alone (with a PET CR) who then develops an isolated CNS relapse?
If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...
1 Answer available
How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?
Ki67  = 90% with multiple small nodes on PET scan and normal CBC
1 Answer available
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
2 Answers available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available
How long should patients treated with frontline therapy for Hodgkin lymphoma wait before attempting to conceive a child?
Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...
1 Answer available
Do you intensify treatment for patients with double-hit lymphoma or double expressor lymphoma?
How does age play a role in this decision?  If you do intensify therapy, how do you explain the negative results of CALGB/Alliance 50303?
5 Answers available
Is there an absolute IgM level, in an asymptomatic patient on surveillance that initiation of therapy would be considered for Waldenstrom's macroglobulinemia?
Does the rate of progression of IgM influence your decision?
1 Answer available
What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?
Would you use ALK inhibitors such as crizotinib based on recent phase II data? Are there any research efforts to combine ALK inhibitors with current ...
1 Answer available
Do you offer maintenance rituximab in transplant ineligible patients with mantle cell lymphoma?
Are there any subsets of patients that you're more inclined to offer maintenance?
1 Answer available
Can radiation therapy alone for localized recurrence of high-grade B-cell lymphoma be considered for those that previously received rituximab-based chemotherapy?
In particular, for frail patients to avoid toxicity or for those that do not want chemotherapy
1 Answer available
Would you consider use of upfront BV plus nivolumab to treat Hodgkin Lymphoma in elderly patients unable to receive standard chemotherapy?
Are there other regimens you employ for patients unsuitable for standard chemotherapy?
1 Answer available
How do you treat a low-grade B-cell lymphoma with plasmacytic differentiation (Waldenstrom's) confined to the CNS?
1 Answer available
How would you approach treatment of a bulky stage II DLBCL in a patient >80 with a contraindication to anthracyclines but otherwise good performance status?
2 Answers available
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
3 Answers available
Would you initiate chemoimmunotherapy (e.g. RCHOP) in a symptomatic patient with DLBCL who tested positive for COVID19?
1 Answer available
How would you manage a stage IE DLBCL of the stomach, non-germinal center type by IHC, and Ki-67 of 70%, but negative for double/triple hit by FISH?
Would you use R-CHOP or a more intensive chemotherapy regimen?  Would you consolidate with radiation therapy after 3 cycles or use systemic thera...
1 Answer available
How do you approach patients with a history of lymphoma in remission who are in need of immunosuppressive (e.g. TNF blockers, 6MP) or other therapies (e.g. JAK inhibitors) for autoimmune disease that have been linked with the development of lymphoma?
1 Answer available
How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?
1 Answer available
How would you manage a patient with Stage IVB DLBCL with refractory disease in the retroperitoneum and spleen after 6 cycles of RCHOP?
Would you offer refractory doses (40-50 Gy) to the RPnodes and send for splenectomy? Or would you offer refractory doses to both RP nodes and spleen?&...
3 Answers available
For AYA patients with early-stage Hodgkin's lymphoma being treated with ABVD, how many cycles of chemotherapy do you administer, and when can radiation be avoided?
Have the RAPID or CALGB 5064 studies changed your treatment approach?
2 Answers available
Would you offer rituximab maintenance for 2 years after a successful response to induction in a patient with splenic marginal zone lymphoma?
When do you consider splenectomy? Is there a role for splenic radiation in non-surgical candidates?
2 Answers available
Would you consider splenectomy for an early stage l/ll primary splenic diffuse large B cell lymphoma followed by R-CHOP?
An otherwise healthy patient with spleen only diffuse large B cell lymphoma with mild spleenomegaly, Spleenectomy plus Rchop or Rchop plus RT? 
1 Answer available
Would you offer treatment for asymptomatic CLL with WBC of ~300k or greater, high risk cytogenetics, or doubling time of 6-12 months?
1 Answer available
How would you treat stage IV DLBCL with severe liver involvement?
1 Answer available
How would you approach a fit older (>70 years) with grade I-II, bulky, follicular lymphoma causing ureteral obstruction and renal failure?
Bulky adenopathy compressed bilateral ureters, CrCl < 30, post stent placement, but renal function has plateaued
2 Answers available
What is your preferred treatment for non-contiguous Stage IIA Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL)?
NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario.  What factors help your decision making?
1 Answer available
How do you approach CNS prophylaxis in double-hit lymphoma patients?
Do you only give intrathecal chemotherapy or systemic therapy?
1 Answer available
What is the role of radiation in a patient with stage IV DLBCL with bilateral testicular involvement?
1 Answer available
How do you approach B-cell lymphoblastic lymphoma (without bone marrow involvement) in older adults (>65-70 years)?
Do you treat as you would a B-ALL? Does amount of nodal stations/disease matter?
1 Answer available
Do you rebiopsy grade 1-2 follicular lymphoma if SUV is high by PET?
What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?
0 Answers available
How would you treat a young patient with symptomatic Rosai-Dorfman disease who has recurrent, life-threatening pericardial and pleural effusions?
CT scans show omental and pelvic disease.
1 Answer available
How do you dose chemotherapy (R-EPOCH or R-CHOP) in patients with aggressive lymphoma involving liver leading to elevated bilirubin and liver enzymes?
1 Answer available
How would you approach langerhans cell histiocytosis involving a single bone site after resection?
1 Answer available
How would you approach a patient with advanced stage DLBCL with a single-site of residual FDG-avid disease after completion of R-CHOP in the frontline setting?
Would you consider this refractory disease and go on to salvage regimen and auto-SCT, or is there a role for definitive XRT to the site of residual di...
1 Answer available
Do you offer adjuvant chemoimmunotherapy after IFRT for Stage I to II low grade follicular lymphoma?
TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...
2 Answers available
Do you routinely recommend consolidative radiation to bulky site(s) in the setting of advanced stage DLBCL?
1 Answer available
What frontline treatment would you offer a patient with AITL who is not a candidate for an anthracycline due to baseline cardiomyopathy?
1 Answer available
Would you choose a different anti-CD20 antibody in early relapsed (< 6 months) DLBCL treated with rituximab?
Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?
1 Answer available
What is your approach to advanced Hodgkin Lymphoma when bleomycin is contraindicated and infectious complications arise with A-AVD?
1 Answer available
What is your preferred induction regimen for primary CNS lymphoma in a young patient?
1 Answer available
Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?
What if the patient has a history of confirmed COVID-19 but has since recovered?
1 Answer available
How do you determine whether to treat a young adult with stage IA Hodgkin Lymphoma with the adult or pediatric treatment paradigm?
At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...
2 Answers available
Should maintenance rituximab be held due to COVID-19 in patients with advanced bulky follicular lymphoma who attain a PR/CR to weekly rituximab?
1 Answer available
Would you consider giving ESA for anemia secondary to chronic kidney disease in a patient with follicular lymphoma in remission and on rituximab maintenance?
1 Answer available
How do you decide on the modality of consolidative treatment after a CR in primary CNS lymphoma patients treated with a high-dose methotrexate regimen?
How do you decide between WBRT, maintenance chemotherapy, or stem cell transplantation? 
2 Answers available
In what situations do you utilize G-CSF in germ cell tumors or Hodgkin lymphoma patients receiving bleomycin?
There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.
2 Answers available
How would you treat Burkitt Lymphoma during an uncomplicated pregnancy?
1 Answer available
What is your preferred salvage chemotherapy regimen for bridge to auto SCT for patients with relapsed classical Hodgkin Lymphoma?
There are multiple regimens including IGEV and most recently reported results of BEGEV without preference on NCCN guidelines.
2 Answers available
Would you give CNS prophylaxis to a patient with Waldeyer's ring diffuse large B cell lymphoma if it is not triple or double hit ?
Risk of CNS relapse in a reported series is less than 5%.
1 Answer available
How would you approach primary CNS lymphoma in an elderly patient over 80 years old?
1 Answer available
How does your approach differ when managing a "triple hit" versus a "double hit" or "double expressor" lymphoma?
Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...
1 Answer available
What is the preferred approach for gastric MALT lymphoma with histologic and radiographic partial response after radiation?
 Would you monitor or directly offer systemic therapy? 
1 Answer available
Is there a role for maintenance lenalidomide after non anthracycline regimens in elderly patients with DLBCL?
1 Answer available
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
0 Answers available
Would you offer consolidative autologous stem cell transplant in CR1 for high risk diffuse large B-cell lymphoma (DLBCL)?
Would your choice be affected by which high risk features the patient has (eg. double- or triple-hit status vs IPI score of 3-4)?
3 Answers available
Would you substitute vinblastine for vincristine in RCHOP?
There is a national shortage of vincristine.
1 Answer available
How long do you treat recurrent classical Hodgkin lymphoma with brentuximab/nivolumab if the patient does not want to proceed to BMT?
1 Answer available
How do you decide on a salvage regimen for relapsed/refractory DLBCL, assuming a patient is transplant eligible?
There are multiple options that carry a category 2B recommendation in the NCCN guidelines. Does germinal B center type vs activated B-cell type play a...
0 Answers available
What dosing schedule of cladribine do you use for newly diagnosed hairy cell leukemia in need of treatment?
1 Answer available
Can a rituxumab biosimilar be used for a high grade lymphoma?
1 Answer available
How do you manage patients who develop de novo or recurrent skin cancers (SCC or BCC) while on lenalidomide?
Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...
1 Answer available
What is the preferred approach for giving high dose methotrexate in double or triple hit lymphomas being treated with dA-EPOCH-R?
2 Answers available
Do you consider discontinuing brentuximab in stage III-IV classical Hodgkin lymphoma patients on AVD+brentuximab who have a good response to 2 cycles?
(ie Deuvelle criteria 1-3) Is it appropriate to discontinue brentuximab like you would with bleomycin?
1 Answer available
How do you approach maintenance therapy for relapsed follicular lymphoma?
Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...
1 Answer available
What would be your choice for treatment for an HIV positive patient with no detectable viral load with CD20 negative and CD30 positive DLBCL?
1 Answer available
Would you offer maintenance lenalidomide or rituximab in a patient with DLBCL transformed from a marginal zone lymphoma in a young, fit patient?
1 Answer available
Do you alter your management of Stage I-II DLBCL if it's double or triple hit?
Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?
0 Answers available
How do you treat a composite NHL of various subtypes?
e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...
1 Answer available
Are you de-escalating treatment for favorable risk Stage I-II DLBCL patients to 4 cycles of R- CHOP with 2 additional rituximab cycles?
Have you changed your practice based off the FLYER trial presented at ASH 2018?
4 Answers available
How would you approach treatment of DLBCL in a patient on hemodialysis?
How would you handle high risk features (eg double hit) with the limitations of dialysis?
2 Answers available
Is there a role at this time for chemo-immunotherapy in the upfront treatment of classic Hodgkin lymphoma?
Although not approved, for example, are you every using AVD-nivolumab?
0 Answers available
When treating DLBCL with induction therapy with R-CHOP, if after 2 cycles, you have a mixed response on PET, would you consider that treatment failure or would you continue R-CHOP?
2 Answers available
How would you treat an elderly fit patient with stage IE DLBCL (single skin lesion)?
Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...
2 Answers available
What is your first line treatment of choice for advanced (stage IIIA) follicular lymphoma, histologic grade 1-2 in an otherwise young healthy patient in 2019?
Assuming the patient has an indication for treatment.
0 Answers available
Is a very rapidly rising WBC count ever an indication for the upfront treatment of CLL?
Assuming there are no other indications at the moment. 
1 Answer available
What is your approach for bulky stage I primary mediastinal B-cell lymphoma in a patient with a positive post-chemotherapy PET-CT (residual mass and Deauville 5)?
Some specific questions: Would you recommend repeat biopsy to confirm residual disease? How would your recommendations vary if the patient had pre...
2 Answers available
For inpatient treatment of lymphoma and ALL, can rituximab be delayed?
I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...
2 Answers available
How do you approach front line treatment for TP53 mutated mantle cell lymphoma?
Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...
2 Answers available
What would be the preferred chemotherapy regimen in elderly patients with advanced stage classical Hodgkin Lymphoma and contraindication to doxorubicin and bleomycin?
1 Answer available
Should consolidation autologous stem cell transplant be considered for de novo follicular lymphoma transformation to DLBCL after achieving a PR with R-CHOP x 6 cycles, if residual disease showed original indolent follicular lymphoma?
1 Answer available
For an otherwise healthy individual, what would be your front line choice for de novo Richter’s transformation?
Pathology is clear this is not a concurrent DLBCL and is indeed transformed CLL
1 Answer available
How would you treat low grade follicular lymphoma with diffuse epidural involvement? Would you give intratheracal or high dose systemic methotrexate in addition to systemic chemoimmunotherapy?
1 Answer available
How early have you been able to detect a response with CAR-T in patients with relapsed DLBCL?
3 Answers available
What is your preferred chemotherapy regimen for a fit younger patient with mantle cell lymphoma?
1 Answer available
What recommendations do you make regarding the use of biologics for uncontrolled Crohn's disease in patient's who have a history of DLBCL that developed while on infliximab and azathioprine and whose lymphoma is essentially cured?
I have received inquiry from a patient's gastroenterologist regarding use of Entyvio or Stelara in such a situation.
1 Answer available
Do you routinely order double-hit assessment in cutaneous DLBCL?
1 Answer available
With new data now available for use of brentuximab in ALK positive, CD30 anaplastic large cell lymphoma, what is your first line regimen?
1 Answer available
How do you approach fit patients with quickly relapsed Hodgkin lymphoma (disease-free interval less than or equal to one year) after 6 cycles of ABVD and radiation therapy?
Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?
1 Answer available
Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?
Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...
1 Answer available
Which regimen do you prefer for patients with newly diagnosed DLBCL that are not candidates for doxorubicin secondary to low ejection fraction?
Do you use etoposide-based regimens such as R-CEPP? How about substitution with liposomal doxorubicin?
1 Answer available
In which patients with early-stage favorable Hodgkin's lymphoma, if any, would you consider omitting consolidation RT after ABVD chemotherapy?
2 Answers available
How do you approach incidentally diagnosed mantle cell lymphoma found on a routine screening colonoscopy?
1 Answer available
How would you treat a younger patient with relapsed mantle cell lymphoma after treatment with hyperCVAD?
How about if disease is found in the CSF?
2 Answers available
What is your alternative first line approach to follicular lymphoma that requires treatment if initial treatment with BR leads to significant neutropenia despite G-CSF?
Would you consider switching regimens?
1 Answer available
How would you treat an elderly, transplant-ineligible patient with recurrent DLBCL?
Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?
1 Answer available
What is your approach to treating limited stage DLBCL of the colon?
1 Answer available
What is the role for maintenance lenalidomide in elderly patients with DLBCL?
Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?
1 Answer available
Do you routinely add eight extra rituximab doses to six cycles of R-CHOP in elderly patients with DLBCL treated with miniR-CHOP as done in SMARTE-R-CHOP-14 trial ?
1 Answer available
Does anything need to be done if hyperlymphocytosis (i.e. ALC > 300K) develops in a CLL patient just starting ibrutinib?
1 Answer available
Does CD5 positivity by itself in DLBCL pose a high risk of CNS recurrence and necessitate CNS prophylaxis?
1 Answer available
In classical hodgkin's lymphoma patients with a postive PET after 2 cycles, are you routinely transitioning to escalated BEACOPP?
Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...
4 Answers available
Do you have a preferred strategy for front line induction therapy in DLBCL patients who have asymptomatic depressed ejection fraction and thus concern about anthracycline dosing?
2 Answers available
What is your approach to treating relapsed subcutaneous panniculitis-like T-cell lymphoma?
Does it differ from the treatment of other relapsed peripheral T-cell lymphomas? Are there any clinical trials or case series focused on SPTCL? Is t...
1 Answer available
How do you approach previously treated grade 1 follicular lymphoma now with transformation to a large cell lymphoma?
1 Answer available
What chemotherapy regimen would you recommend for a patient with symptomatic cutaneous B cell lymphoma?
Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...
1 Answer available
Would you use Ibrutinib plus Venetoclax as second line therapy in relapsed/refractory mantle cell lymphoma?
The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and show...
2 Answers available
How would you approach a completely resected DLBCL of the appendix if PET scan and bone marrow biopsy suggest no other disease?
2 Answers available
Would you consolidate marginal zone lymphoma transformed to a high grade B-cell lymphoma with a stem cell transplant?
the MZL was untreated in the past prior to transformation. Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...
1 Answer available
How would you approach a Follicular grade 1-2 NHL found on a terminal ileum biopsy with otherwise negative EGD and colonoscopy and contrast enhanced CT scan?
Would you consider resection? Or maybe anti-CD20 monoclonal antibody?
2 Answers available
What growth factor would you use with A+AVD, if any at all?
If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.
1 Answer available
Do you prefer a chemo-radiation combination or chemotherapy followed by sequential radiation approach for early stage NK/T-cell lymphoma?
1 Answer available
How do you approach the development of an LGL clone in a NHL patient actively getting therapy?
1 Answer available
How would you treat stage 3 lymphocyte-predominant Hodgkin Lymphoma that is CD20 negative ?
1 Answer available
Are there any indications on advanced stage Hodgkins disease that one might consider stopping the bleomycin after first two cycles?
Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?
1 Answer available
What is the role of radiation treatment of stage IA ALK negative anaplastic large cell lymphoma?
PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...
2 Answers available
What is your approach to the upfront treatment of anaplastic large cell lymphoma, ALK positive, with low IPI score in a young person?
With the advent of many new agents, any thought to initial therapy different from CHOP or CHOEP?
1 Answer available
What is the optimal regimen for advanced stage Nodular Lymphocyte Predominant Hodgkin Lymphoma?
1 Answer available
Does rituximab + lenalidomide have a role in advanced follicular lymphoma?
Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...
1 Answer available
Do you use anti-microbial prophylaxis when you prescribe ibrutinib?
If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?
1 Answer available
Do you choose to include or omit growth factor support in the treatment of Hodgkins lymphoma?
1 Answer available
When determining treatment approach to newly-diagnosed follicular lymphoma (e.g. watchful waiting vs chemotherapy), do you take the intensity of the SUV measurements on PET into account?
1 Answer available
What is your preferred approach to a patient with newly diagnosed primary mediastinal B-cell lymphoma in the upfront setting?
Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?
1 Answer available
For patients with stage 1A-E extra nodal marginal zone lymphoma that has been completely excised, would you still consider radiation?
NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...
1 Answer available
Which chemotherapy regimen would you choose for a female adolescent with favorable prognosis stage I-II Classical Hodgkin lymphoma, assuming the patient prefers not to do IFRT if the initial PET response is good?
0 Answers available
What is the role of radiation consolidation after chemotherapy for residual splenic involvement in follicular lymphoma?
1 Answer available
Is there a role for consolidation radiation in a patient with stage I low grade follicular lymphoma treated with chemotherapy?
If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...
1 Answer available


Papers discussed in this category

J. Clin. Oncol., 2014-04-10
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.
J. Clin. Oncol., 2013-11-10
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.
Oncology (Williston Park, N.Y.), 2012-12
Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks.
N. Engl. J. Med., 2010-08-12
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
British journal of haematology, 2017-11
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
J Clin Oncol, 2010 Oct 10
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
J. Natl. Cancer Inst., 2011 Oct 21
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
The Lancet. Oncology, 2016-08
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
J. Clin. Oncol., 2010 May 03
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
Blood, 2016-10-13
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
The Lancet. Oncology, 2014-11
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
The New England journal of medicine, 2016-06-23
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Blood, 2013-12-19
How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Cancer, 2004-05-15
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
N. Engl. J. Med., 2018-01-25
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
Lancet, 2009 Sep 18
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
J Clin Oncol, 2023 May 16
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 04
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Dec 10
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Lancet, 2021 Mar 06
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05
Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
British journal of haematology, 2018-10
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Blood Adv,
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
The New England journal of medicine, 2017-12-28
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Avicenna J Med, 2017 Jul-Sep
An unusual presentation of chronic lymphocytic leukemia.
Blood,
Primary central nervous system lymphoma.
J. Clin. Oncol.,
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Lancet (London, England), 2018-02-17
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
J. Clin. Oncol., 2018 Jul 05
Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
Lancet (London, England), 2019-01-19
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Outcome of deferred initial therapy in mantle-cell lymphoma.
J. Clin. Oncol., 2009 Oct 05
Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
Ann. Oncol.,
Observation as the initial management strategy in patients with mantle cell lymphoma.
Cancer Res., 2010 Feb 02
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.
Haematologica, 2019-04
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
Dig Liver Dis, 2013 Jun 28
Primary intestinal B-cell lymphoma: a prospective multicentre clinical study of 91 cases.
Am. J. Clin. Oncol.,
Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
Blood, 2018 Sep 04
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Blood, 2017-02-02
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
The Lancet. Haematology, 2016-05
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
The Lancet. Haematology, 2017-11
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Eur J Haematol, 2023 Mar 27
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Blood, 2018-03-15
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Neuro-oncology, 2009-04
High-dose methotrexate for elderly patients with primary CNS lymphoma.
Lancet Haematol, 2015 Jun 03
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Radiother Oncol, 2011 Jun 12
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.
Haematologica, 2016 Jun 16
Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Haematologica, 2017 Sep 21
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
British journal of haematology, 2015-12
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Blood Adv,
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
The Lancet. Oncology, 2014-03
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Leukemia, 2019-01
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
Blood, 2017 Aug 3
How I treat double-hit lymphoma.
Blood, 2018 Apr 19
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
J. Clin. Oncol., 2011 Sep 26
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
The Lancet. Oncology, 2018-02
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
British journal of haematology, 2016-06
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Chest, 1997-03
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
J. Clin. Oncol.,
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Clin Genitourin Cancer, 2017 Sep 04
Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.
Eur. Urol., 2020 Jan 01
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
J. Clin. Oncol., 2019 Sep 10
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Blood, 2019-05-16
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood,
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
N Engl J Med, 2021 Dec 11
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Lancet,
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
International journal of radiation oncology, biology, physics, 2012-11-01
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Lancet Oncol., 2008 Jan 15
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Haematologica, 2020
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
Nature, 2019-03
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Blood, 2018 May 02
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Leuk Lymphoma, 2019 Dec 26
Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease).
Cancer, 2008-10-15
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
The Lancet. Oncology, 2018-02
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Blood,
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood,
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Chinese clinical oncology, 2015-03
Staging and response assessment in lymphomas: the new Lugano classification.
Leukemia & lymphoma, 2017-12
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24
Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study.
Lancet Oncol., 2014-04-01
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.
Blood, 2019-01-24
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Blood, 2018 Jun 18
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
Blood, 2018-06-21
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Leukemia, 2020 May 07
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
N. Engl. J. Med., 2015-04-23
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Blood, 2018 Sep 6
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
J Clin Oncol, 2017 Mar 14
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
Blood, 2015 Sep 17
How I treat posttransplant lymphoproliferative disorders.
Hematol Oncol, 2017 Oct 30
Relapse in stage I(E) diffuse large B-cell lymphoma.
Lancet Haematol, 2020 Oct 01
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
J Clin Oncol, 2013 Nov 12
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Blood Adv,
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.
N Engl J Med,
Treatment of older patients with mantle-cell lymphoma.
Blood, 2011-05-05
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Haematologica, 2016 Dec 01
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Clin Transl Oncol, 2020 Sep 17
ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
J Assist Reprod Genet, 2020 Jun 02
Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
Lancet Oncol, 2018 Sep 13
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
International journal of radiation oncology, biology, physics, 2019-12-01
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
The Lancet. Oncology, 2019-01
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Cancer immunology research, 2019-07
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Br J Haematol, 2020 Mar 5
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Lancet, 2020 Sep 01
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Blood Adv,
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Int J Radiat Oncol Biol Phys, 2020 May 22
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Radiother Oncol, 2021 Dec 7
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Int J Radiat Oncol Biol Phys, 2022 Dec 20
Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.
Transplant Cell Ther, 2022 Dec 30
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Blood advances, 2020 Jul 28
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26
Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Blood advances, 2020 Nov 24
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Haematologica, 2023 Jun 15
Consolidative radiotherapy for residual FDG activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.
Haematologica, 2021 Jun 01
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
The New England journal of medicine, 2015-11-05
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Haematologica, 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Blood,
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Leukemia, 2011 Jul 01
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Haematologica, 2019 Sep 19
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Blood, 2017 Aug 17
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood, 2015 May 28
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
The New England journal of medicine, 2019-06-06
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
J Clin Oncol, 2021 Jul 26
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Leukemia, 2022 Jan 01
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Blood Adv,
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.
Pediatric blood & cancer, 2007-02
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
Blood, 2021 Nov 15
An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis.
Lancet Haematol, 2019 Sep 16
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
J Clin Oncol, 2016 Feb 29
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Lancet Haematol, 2016 Dec 05
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Oncol, 2022 Jan 21
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
N Engl J Med,
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Hematology (Amsterdam, Netherlands), 2019-12
Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.
Lancet Oncol, 2020 Jun 05
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
J Clin Oncol, 2019 Nov 06
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
J Clin Oncol, 2022 Dec 22
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Blood Adv, 2022 May 10
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Blood, 2022 Dec 15
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Ann Oncol, 2009 Jul 01
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood, 2010 Jul 21
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Lupus, 2019 Jun 19
Prognostic markers of lymphoma development in primary Sjögren syndrome.
Ann Rheum Dis, 2011 Nov 09
Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan.
Blood, 2022 Mar 03
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Cancer cell, 2017-06-12
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
J Neurooncol, 2022 Jun 20
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
Blood, 2004-09-15
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
J Clin Oncol, 2015 Dec 07
Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lancet Oncol, 2022 Jul 12
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
J Clin Oncol, 2017 Jan 17
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Blood, 2013-08-08
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
British journal of haematology, 2016-03
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-10
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
International journal of hematology-oncology and stem cell research, 2021 Oct 01
Hodgkin Variant of Richter's Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review.
Blood, 2020 Apr 09
Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.
Cancer, 2018-06-15
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
The Lancet. Oncology, 2021 Dec 08
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jul 28
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
The New England journal of medicine, 2022 Feb 24
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
N Engl J Med, 2023 Jul 6
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Blood advances, 2023 Jun 27
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Blood advances, 2022 Oct 25
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
The Lancet. Oncology, 2018-01
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
The New England journal of medicine, 2018-03-22
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Blood advances, 2024 Mar 26
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Haematologica, 2024 Jun 01
Pirtobrutinib venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Blood advances, 2023 Sep 26
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Neurooncol Adv, 2023 Jan-Dec
Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma.

Related Topics in Medical Oncology

Copyright © 2024 theMednet
All Rights Reserved.